Utility of Virtual Crossmatch in Sensitized Patients Awaiting Heart Transplantation

Journal of Heart and Lung Transplantation

Volumn 28, Issue 11, 2009, Pages 1129-1134

  Stehlik, Josef ^a,b   Islam, Nauman ^a   Hurst, Denise ^a   Kfoury, Abdallah G ^c   Movsesian, Matthew A ^b   Fuller, Ann ^a   Delgado, Julio C ^a   Hammond, M Elizabeth H ^c   Gilbert, Edward M ^a   Renlund, Dale G ^c   Bader, Feras ^a   Fisher, Patrick W ^c   Bull, David A ^a   Singhal, Arun K ^a   Eckels, David D ^a  

^a UNIVERSITY OF UTAH HOSPITAL   (United States)

^b Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program   (United States)

^c INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HLA ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; T LYMPHOCYTE ANTIBODY; TACROLIMUS;

ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART TRANSPLANTATION; HLA TYPING; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; ORGAN DONOR; PLASMAPHERESIS; PRIORITY JOURNAL; SENSITIZATION; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; ENDOMYOCARDIAL FIBROSIS; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; POSTOPERATIVE COMPLICATIONS; PROCOLLAGEN-PROLINE DIOXYGENASE; TIME FACTORS; USER-COMPUTER INTERFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350199610     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.05.031     Document Type: Article

References (26)

1. Patel R., and Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280 (1969) 735-739
2. Gebel H.M., Bray R.A., and Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 3 (2003) 1488-1500
3. Vo A.A., Lukovsky M., Toyoda M., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359 (2008) 242-251
4. Zangwill S., Ellis T., Stendahl G., Zahn A., Berger S., and Tweddell J. Practical application of the virtual crossmatch. Pediatr Transplant 11 (2007) 650-654
5. Jordan S.C., Vo A., Bunnapradist S., et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 76 (2003) 631-636
6. Akalin E., Dinavahi R., Friedlander R., et al. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 3 (2008) 1160-1167
7. Jordan S.C., Tyan D., Stablein D., et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 15 (2004) 3256-3262
8. Gonzalez-Stawinski G.V., Cook D.J., Smedira N.G., et al. Attrition from heart transplant waiting list for patients on ventricular assist devices is not affected by desensitization strategies. Transplantation proceedings 39 (2007) 1571-1572
9. Pei R., Lee J.H., Shih N.J., Chen M., and Terasaki P.I. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 75 (2003) 43-49
10. Bray R.A., Nolen J.D., Larsen C., et al. Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant 6 (2006) 2307-2315
11. Kerman R., Lappin J., Kahan B., et al. The crossmatch may still be the most clinically relevant histocompatibility test performed. Clin Transpl (2007) 227-229
12. Vaidya S. Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 85 (2008) 1046-1050
13. Zangwill S.D., Ellis T.M., Zlotocha J., et al. The virtual crossmatch-a screening tool for sensitized pediatric heart transplant recipients. Pediatr Transplant 10 (2006) 38-41
14. Appel III J.Z., Hartwig M.G., Cantu III E., Palmer S.M., Reinsmoen N.L., and Davis R.D. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 81 (2006) 1049-1057
15. Kobashigawa J., Mehra M., West L., et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant 28 (2009) 213-225
16. Johnson A.H., Rossen R.D., and Butler W.T. Detection of alloantibodies using a sensitive antiglobulin microlymphocytotoxicity test. Tissue Antigens 2 (1972) 215
17. Amos D.B. Tissue typing. Vox Sanguinis 11 (1996) 261
18. Yang J., Schall C., Smith D., et al. HLA sensitization in pediatric pre-transplant cardiac patients supported by mechanical assist devices: the utility of Luminex. J Heart Lung Transplant 28 (2009) 123-129
19. Joyce D.L., Southard R.E., Torre-Amione G., Noon G.P., Land G.A., and Loebe M. Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes. J Heart Lung Transplant 24 (2005) 2054-2059
20. Drakos S.G., Stringham J.C., Long J.W., et al. Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions. J Thorac Cardiovasc Surg 133 (2007) 1612-1619
21. Mizutani K., Terasaki P., Hamdani E., et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 7 (2007) 1027-1031
22. Vaidya S., and Ruth J. Contributions and clinical significance of IgM and autoantibodies in highly sensitized renal allograft recipients. Transplantation 47 (1989) 956-958
23. Khodadadi L., Adib M., and Pourazar A. Immunoglobulin class (IgG, IgM) determination by dithiothreitol in sensitized kidney transplant candidates. Transplantation proceedings 38 (2006) 2813-2815
24. Reinsmoen N.L., Lai C.H., Vo A., et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 86 (2008) 820-825
25. Vo A.A., Toyoda M., Peng A., Bunnapradist S., Lukovsky M., and Jordan S.C. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 6 (2006) 2384-2390
26. Magee C.C., Felgueiras J., Tinckam K., Malek S., Mah H., and Tullius S. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience. Transplantation 86 (2008) 96-103